These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 18673288

  • 1. Antibody-onconase conjugates: cytotoxicity and intracellular routing.
    Rybak SM.
    Curr Pharm Biotechnol; 2008 Jun; 9(3):226-30. PubMed ID: 18673288
    [Abstract] [Full Text] [Related]

  • 2. Anti-CD22 Onconase: preparation and characterization.
    Newton DL, Stockwin LH, Rybak SM.
    Methods Mol Biol; 2009 Jun; 525():425-43, xiv. PubMed ID: 19252847
    [Abstract] [Full Text] [Related]

  • 3. A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.
    Weber T, Mavratzas A, Kiesgen S, Haase S, Bötticher B, Exner E, Mier W, Grosse-Hovest L, Jäger D, Arndt MA, Krauss J.
    J Immunol Res; 2015 Jun; 2015():561814. PubMed ID: 26605343
    [Abstract] [Full Text] [Related]

  • 4. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma.
    Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM, Rybak SM.
    Blood; 2001 Jan 15; 97(2):528-35. PubMed ID: 11154233
    [Abstract] [Full Text] [Related]

  • 5. Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapy.
    Krauss J, Arndt MA, Dübel S, Rybak SM.
    Curr Pharm Biotechnol; 2008 Jun 15; 9(3):231-4. PubMed ID: 18673289
    [Abstract] [Full Text] [Related]

  • 6. [Onconase: a ribonuclease with antitumor activity].
    Zwolińska M, Smolewski P.
    Postepy Hig Med Dosw (Online); 2010 Feb 19; 64():58-66. PubMed ID: 20173221
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.
    Ardelt W, Shogen K, Darzynkiewicz Z.
    Curr Pharm Biotechnol; 2008 Jun 19; 9(3):215-25. PubMed ID: 18673287
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ribonucleases and immunoRNases as anticancer drugs.
    Rybak SM, Arndt MA, Schirrmann T, Dübel S, Krauss J.
    Curr Pharm Des; 2009 Jun 19; 15(23):2665-75. PubMed ID: 19689337
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Targeted therapeutic RNases (ImmunoRNases).
    Schirrmann T, Krauss J, Arndt MA, Rybak SM, Dübel S.
    Expert Opin Biol Ther; 2009 Jan 19; 9(1):79-95. PubMed ID: 19063695
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
    Shor B, Gerber HP, Sapra P.
    Mol Immunol; 2015 Oct 19; 67(2 Pt A):107-16. PubMed ID: 25304309
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.